H · S · G
Huntington · Study · Group
Results of an 8-Week Double-Blind, Placebo-Controlled, Multi-Center Study by the Huntington Study Group
Under the direction of Merit Cudkowicz, MD, MSc, Principal Investigator
of the minocycline (MINO) trial, the HSG conducted an 8-week study of
minocycline in Huntington’s disease (HD). The study was designed
to assess whether the drug was safe and tolerable in two dosages compared
to placebo over a relatively short period of time. The study was conducted
by the Huntington Study Group (HSG), a consortium of physicians, psychologists,
and other health professionals throughout the US and Canada. There were
sixty participants with Huntington’s disease enrolled at 8 participating
HSG sites in North America. Over eight weeks of study, minocycline at
100 mg and 200 mg per day was well tolerated and safe in HD patients.
The HSG is planning a longer duration study of minocycline to begin to
look at efficacy and long term safety.
HSG Overview | Huntington's Disease Overview | What is a Clinical Trial?
Clinical Trials in Progress | New Clinical Trial Initiatives Completed Clinical Trials
HSG Working Groups | HSG / MDS Symposia Publications / Abstracts
What's New? | UHDRS | Contributions| Other useful links | HSG Research Sites